×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KZR – kezar life sciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KZR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/25
08:00 am
kzr
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results [Yahoo! Finance]
Medium
Report
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results [Yahoo! Finance]
3/25
07:30 am
kzr
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Medium
Report
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
3/24
08:29 am
kzr
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 [Yahoo! Finance]
Medium
Report
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 [Yahoo! Finance]
3/24
08:00 am
kzr
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Medium
Report
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
2/28
12:30 pm
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "outperform" rating re-affirmed by analysts at William Blair.
2/18
04:41 pm
kzr
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 [Yahoo! Finance]
Medium
Report
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 [Yahoo! Finance]
2/18
04:01 pm
kzr
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
Medium
Report
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
2/5
05:46 pm
kzr
Kezar Life Sciences files for $400M mixed securities shelf [Seeking Alpha]
Medium
Report
Kezar Life Sciences files for $400M mixed securities shelf [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
3/25/2025
07:30 am
kzr
kezar life sciences, inc.
MISS
Report
-10.5%
kezar life sciences, inc.
Date
Time
Symbol
Headline
Impact
4/16
04:41 pm
kzr
Form 3 Kezar Life Sciences, For: Apr 01 Filed by: Chiang Pichi Luo
Neutral
Report
Form 3 Kezar Life Sciences, For: Apr 01 Filed by: Chiang Pichi Luo
4/16
04:40 pm
kzr
Form 3 Kezar Life Sciences, For: Apr 01 Filed by: To Zung Phoung
Neutral
Report
Form 3 Kezar Life Sciences, For: Apr 01 Filed by: To Zung Phoung
4/1
08:42 pm
kzr
Form 4 Kezar Life Sciences, For: Mar 27 Filed by: Schiller Mark C.
Low
Report
Form 4 Kezar Life Sciences, For: Mar 27 Filed by: Schiller Mark C.
4/1
08:41 pm
kzr
Form 4 Kezar Life Sciences, For: Mar 27 Filed by: Belsky Marc
Low
Report
Form 4 Kezar Life Sciences, For: Mar 27 Filed by: Belsky Marc
4/1
04:06 pm
kzr
Form 8-K Kezar Life Sciences, For: Mar 27
Low
Report
Form 8-K Kezar Life Sciences, For: Mar 27
3/25
07:48 am
kzr
Form 10-K Kezar Life Sciences, For: Dec 31
Medium
Report
Form 10-K Kezar Life Sciences, For: Dec 31
3/25
07:43 am
kzr
Form 8-K Kezar Life Sciences, For: Mar 25
Medium
Report
Form 8-K Kezar Life Sciences, For: Mar 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/5
Form 4 Kezar Life Sciences, For: Feb 04 Filed by: Economides Vassiliki
28.2%
1/30 Form 8-K Kezar Life Sciences, For: Jan 30 26.9%
2/10 Form SC 13G/A Kezar Life Sciences, Filed by: AMGEN INC 24.0%
4/9 Kezar Provides Statement Regarding COVID-19 Pandemic 9.7%
12/19 Form 3 Kezar Life Sciences, For: Dec 18 Filed by: Garner Elizabeth 8.4%
6/27 Form 4 Kezar Life Sciences, For: Jun 25 Filed by: BERGER FRANKLIN M 7.5%
10/1 Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting 6.8%
12/19 Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors 6.3%
8/12 Form 4 Kezar Life Sciences, For: Aug 09 Filed by: Fowler John Franklin 6.2%
12/20 Form 4 Kezar Life Sciences, For: Dec 19 Filed by: Fowler John Franklin 5.7%
1/30 Form 8-K Kezar Life Sciences, For: Jan 30 26.9%
2/10 Form SC 13G/A Kezar Life Sciences, Filed by: AMGEN INC 24.0%
4/9 Kezar Provides Statement Regarding COVID-19 Pandemic 9.7%
12/19 Form 3 Kezar Life Sciences, For: Dec 18 Filed by: Garner Elizabeth 8.4%
6/27 Form 4 Kezar Life Sciences, For: Jun 25 Filed by: BERGER FRANKLIN M 7.5%
10/1 Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting 6.8%
12/19 Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors 6.3%
8/12 Form 4 Kezar Life Sciences, For: Aug 09 Filed by: Fowler John Franklin 6.2%
12/20 Form 4 Kezar Life Sciences, For: Dec 19 Filed by: Fowler John Franklin 5.7%
TOP News Decliners
5/28
Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
-34.0%
2/26 Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference -14.2%
2/7 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -12.9%
6/13 Form 8-K Kezar Life Sciences, For: Jun 13 -12.5%
11/12 Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting -11.2%
3/10 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -11.0%
10/1 Kezar Life Sciences Inc (NASDAQ: KZR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -10.1%
3/14 Kezar Life Sciences Inc (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at William Blair. -7.7%
3/13 Kezar Life Sciences Inc (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Co from $30.00 to $18.00. They now have an "overweight" rating on the stock. -7.4%
6/25 Form 8-K Kezar Life Sciences, For: Jun 25 -7.1%
2/26 Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference -14.2%
2/7 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -12.9%
6/13 Form 8-K Kezar Life Sciences, For: Jun 13 -12.5%
11/12 Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting -11.2%
3/10 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -11.0%
10/1 Kezar Life Sciences Inc (NASDAQ: KZR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -10.1%
3/14 Kezar Life Sciences Inc (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at William Blair. -7.7%
3/13 Kezar Life Sciences Inc (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Co from $30.00 to $18.00. They now have an "overweight" rating on the stock. -7.4%
6/25 Form 8-K Kezar Life Sciences, For: Jun 25 -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: